Headshot of Kirti Sharma
Back to all Perspectives
Area of Focus
Platform
Publish Date
August 17, 2022
Author
Kirti Sharma, PhD, Senior Director, Proteomics

A New Proteomics-Based Tool to Advance Targeted Protein Degradation Precision Medicine

TPD is uniquely positioned to potentially develop safer therapeutics for clinically validated targets through the use of tissue restricted E3 ligases (enzymes which tag these disease-causing proteins for recycling). Tissue restricted degradation overcomes the hurdle by eliminating unwanted toxicity, thereby enhancing the therapeutic window. Kymera is taking a unique approach towards accessing undruggable targets by utilizing our proprietary E3 Ligase Whole Body Atlas.